RITUXIMAB WITH INVOLVED FIELD IRRADIATION FOR EARLY-STAGE DIFFUSE LARGE CELL LYMPHOMA

RITUXIMAB WITH INVOLVED FIELD IRRADIATION FOR EARLY-STAGE DIFFUSE LARGE CELL LYMPHOMA

Objective: Efficacy and safety of Involved Field (IF) radiotherapy in combination for anti-CD20 antibody Rituximab (MabThera) and Involved field Radiotherapy for early-stage Diffuse Large Cell lymphoma (DLBCL) in a prospective, single-arm multicenter study. Methodology: Forty-five stage I–II FL pati...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vera Kovalskaya, Natalya Falaleeva, Stanislav Shklyaev, Andrey Chelmakov, Ludmila Grivtsova, Marwa Abdelgawad, Ahmed Mubarek
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137925001634
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
by: Steven Habbous, et al.
Published: (2020-10-01)

Bone marrow composition features and possibilities of tumor involvement diagnosing in patients with classic Hodgkin’s lymphoma
by: F. M. Abbasbeyli, et al.
Published: (2023-09-01)

Intralesional rituximab in ocular adnexal lymphoma
by: P. Crespo Robledo, et al.
Published: (2014-07-01)

Diffuse involvement of small bowel in burkitt's lymphoma with intussusception
by: Digamber Chaubey, et al.
Published: (2020-01-01)

Renal Involvement in Diffuse Large B-cell Lymphoma
by: Shashikant Saini, et al.
Published: (2024-10-01)

Serum albumin predicts survival in Indian adult diffuse large B cell lymphoma patients in the rituximab era
by: Anshul Gupta, et al.
Published: (2019-01-01)

Diffuse Large B Cell Lymphoma with Cutaneous and Gastrointestinal Involvement
by: Aye-Mya-Mya Kyaw, et al.
Published: (2022-01-01)

Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study
by: Irene Dogliotti, et al.
Published: (2024-07-01)

Loss of CD20 Expression in Follicular Lymphoma after Program Anti-Tumor Therapy Including Rituximab: Literature Data and Case Report
by: OM Volodina, et al.
Published: (2017-04-01)

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
by: Paolo Strati, et al.
Published: (2025-08-01)

Effect of rituximab on heart involvement in systemic sclerosis
by: L. A. Garzanova, et al.
Published: (2019-01-01)

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda
by: Manoj P. Menon, et al.
Published: (2025-04-01)

Rituximab for children with EBV-positive Burkitt lymphoma in East Africa
by: William Frank Mawalla, et al.
Published: (2025-05-01)

Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large B-cell lymphoma
by: Enguang Bi, et al.
Published: (2024-11-01)

Diffuse Subcutaneous Scalp Involvement of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
by: Maha Zafar, et al.
Published: (2024-05-01)

A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib
by: Geoffrey Shouse, et al.
Published: (2018-01-01)

Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab
by: Wulyo Rajabto, et al.
Published: (2024-07-01)

The monitoring of B lymphocytes in non-lymphoma patients following rituximab treatment
by: Linjie Dong, et al.
Published: (2024-11-01)

Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma
by: Masaki Suzuki, et al.
Published: (2025-04-01)

Features of CLOCC syndrome in the patient b-lymphoblastic lymphoma. A case report
by: A. Yu. Terekhova, et al.
Published: (2025-05-01)

Efficacy and safety of rituximab-based chemoimmunotherapy in adult patients with Burkitt lymphoma in Korea
by: Gi-June Min, et al.
Published: (2025-07-01)

Acquired angioedema and rituximab-induced acute thrombocytopenia in splenic marginal zone lymphoma
by: Odd Terje Brustugun, et al.
Published: (2025-07-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
by: Partha Sarathi Roy, et al.
Published: (2013-01-01)

Immunocorrective treatment use in the prevention of hematological and infectious complications of chemotherapy in cancer patients
by: L. Yu. Grivtsova, et al.
Published: (2021-11-01)

Craniocerebral involvement in lymphoma
by: Jorge D. Correale, et al.
Published: (1990-09-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Rituximab in pediatric B-cell Non-Hodgkin Lymphoma: Clinical outcomes and prognostic implications
by: Şefika Akyol, et al.
Published: (2025-03-01)

Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma
by: Mihaljević Biljana, et al.
Published: (2008-01-01)

BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.
by: Roberto Castelli
Published: (2016-07-01)

Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients
by: Tamather Almandeel, et al.
Published: (2025-06-01)

Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
by: I. N. Dyakov, et al.
Published: (2022-07-01)

Prognostic significance of AIF expression in diffuse large B-cell lymphoma
by: Vitaly A. Rosin, et al.
Published: (2025-01-01)

Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases
by: Vadim Gorodetskiy, et al.
Published: (2021-04-01)

Long-Term Remission of Primary Bone Marrow Diffuse Large B-Cell Lymphoma Treated with High-Dose Chemotherapy Rescued by In Vivo Rituximab-Purged Autologous Stem Cells
by: Hiroshi Kazama, et al.
Published: (2012-01-01)

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study
by: Allison Barraclough, et al.
Published: (2025-03-01)

Rituximab in the treatment of nodal Bcell marginal zone lymphoma, primary Sjogren’s syndrome and autoimmune hepatitis
by: O A Logvinenko, et al.
Published: (2008-10-01)

Case Report: A very rare case of diffuse large B-cell lymphoma with cardiac and ovarian involvement
by: Yadan Du, et al.
Published: (2025-06-01)

Bilateral renal involvement in diffuse large B-cell lymphoma on fluorodeoxyglucose positron emission tomography/computed tomography
by: Yassir Benameur, et al.
Published: (2021-04-01)